Antibodies

22 Mar 2019 GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
21 Mar 2019 Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
21 Mar 2019 Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
21 Mar 2019 Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
21 Mar 2019 BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
21 Mar 2019 Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
20 Mar 2019 I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States
20 Mar 2019 Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
20 Mar 2019 I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
20 Mar 2019 Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
20 Mar 2019 Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
19 Mar 2019 Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
19 Mar 2019 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
19 Mar 2019 FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
17 Mar 2019 Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
15 Mar 2019 Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
15 Mar 2019 European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
14 Mar 2019 European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
14 Mar 2019 Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission
14 Mar 2019 BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease
13 Mar 2019 Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
13 Mar 2019 FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
13 Mar 2019 Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
13 Mar 2019 Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA®
13 Mar 2019 U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top